Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers believe that in addition to producing antibodies against the virus, vaccines must also give rise to a cellular immune response.
The NIH-funded network has launched its first clinical trial in response to the new pandemic.
Large trial of HIV vaccine finds it does not prevent HIV
Monday, May 18 is HIV Vaccine Advocacy Day. Support science. Not sound bites.
The new coronavirus crisis has upended the clinical trials process around the world.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
The International AIDS Conference takes place July 6 to 10 in San Francisco and Oakland.
Conducted in South Africa, it’s one of three major late-stage trials.
An $80,000 grant from The Campbell Foundation will help scientist Natalia Freund continue her HIV vaccine studies.
Only HIV vax to show any efficacy prompted strong immune response in new study
They’re the 2019 recipients of amfAR’s Mathilde Krim Fellowship in Basic Biomedical Research.
These types of antibodies are able to neutralize a wide breadth of HIV strains.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
“Young researchers such as myself…can provide a new perspective and contribute to the conversation for a cure,” says Chidera Ejikeme.
By altering the components of the vaccine regimen, researchers drove promising antibody and immune-cell responses.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.